D. Boral Capital reaffirmed their buy rating on shares of Kairos Pharma (NYSEAMERICAN:KAPA – Free Report) in a report published on Monday morning,Benzinga reports. The firm currently has a $9.00 price objective on the stock.
Separately, Maxim Group assumed coverage on Kairos Pharma in a research report on Thursday, March 27th. They issued a “buy” rating and a $4.00 price objective on the stock.
View Our Latest Stock Report on Kairos Pharma
Kairos Pharma Stock Performance
Kairos Pharma Company Profile
We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.
Read More
- Five stocks we like better than Kairos Pharma
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- How to Invest in Small Cap Stocks
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to Plot Fibonacci Price Inflection Levels
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Kairos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kairos Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
